Nanologica – Mandatory bid

Flerie Invest AB, reg. no. 556856-6615 (“Flerie“), announced on 25 April 2025, that the company had acquired an additional 666,570 shares in Nanologica AB (publ), reg. no. 556664-5023 (“Nanologica”). After the acquisition, Flerie owns a total of 38,222,779 shares in Nanologica, equivalent to approximately 43.26 percent of all shares and votes in the company. Flerie is a wholly-owned subsidiary of Flerie AB, reg. no. 559067-6820.

Flerie hereby makes a mandatory cash offer to the shareholders of Nanologica to acquire all of the outstanding shares in Nanologica (the “Mandatory Offer”). The shares of Nanologica are admitted to trading on Nasdaq Stockholm. The Mandatory Offer does not include the 38,222,779 shares in Nanologica that are already held by Flerie.

“Nanologica’s groundbreaking nanoporous silica particles for purification of peptides can significantly improve the manufacture of GLP-1 analogues for weight loss, insulin and other peptide-based drugs – global markets that will undoubtedly increase with an ageing population and prevalence of obesity. It is my belief that Nanologica will  become a leader in the field but some do not share that opinion, which is reflected in the share price. Even if the mandatory bid that Flerie is submitting today is unlikely to be accepted by all other shareholders, it provides an opportunity for those who do not wish to be part of the continued journey of the company. We look forward to working with the remaining shareholders to support Nanologica on its exciting journey to become a profitable company.” says Ted Fjällman, CEO of Flerie AB.